Oculis Holding AG (OCS) Shares Outstanding (Weighted Average) (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Shares Outstanding (Weighted Average) of $739.7 million in Q1 2026, up 7.15% quarter-over-quarter from $690.3 million in Q4 2025, and up 43.26% on a YoY basis from $516.3 million in Q1 2025.
Oculis Holding AG (OCS) Shares Outstanding (Weighted Average) (2021 - 2026) Analysis & Trends
Oculis Holding AG's Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $739.7 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) rose 43.26% year-over-year to $739.7 million; the TTM figure through Mar 2026 stood at $739.7 million (up 43.26% YoY), while the FY2025 annual figure was $690.3 million, up 75.31% from the prior year.
- Shares Outstanding (Weighted Average) was $739.7 million for Q1 2026 at Oculis Holding AG, up from $690.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $739.7 million in Q1 2026 to a low of $4.0 million in Q4 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $408.4 million across 5 years, with a median of $393.5 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) jumped 3360.76% in 2022, then grew 20.57% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $4.0 million in 2022, then jumped by 921.99% to $41.3 million in 2023, then soared by 853.03% to $393.8 million in 2024, then soared by 75.31% to $690.3 million in 2025, then advanced by 7.15% to $739.7 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $739.7 million (Q1 2026), $690.3 million (Q4 2025), and $583.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 928.40 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 739.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 739.66 Mn |
| Dec 31, 2025 | 690.31 Mn |
| Sep 30, 2025 | 583.62 Mn |
| Jun 30, 2025 | 563.41 Mn |
| Mar 31, 2025 | 516.30 Mn |
| Dec 31, 2024 | 393.76 Mn |
| Sep 30, 2024 | 393.17 Mn |
| Mar 31, 2024 | 330.40 Mn |
| Dec 31, 2023 | 41.32 Mn |
| Sep 30, 2023 | 326.09 Mn |
| Jun 30, 2023 | 318.86 Mn |
| Dec 31, 2022 | 4.04 Mn |
| Dec 31, 2021 | -123,983.53 |